Loading...
Comparison of toxicities of PARP inhibitors used in gynaecological cancers observed at a large cancer centre
Nagy, Bence Morgan, Robert David Mitchell, Claire L Clamp, Andrew R Hasan, Jurjees
Nagy, Bence
Morgan, Robert David
Mitchell, Claire L
Clamp, Andrew R
Hasan, Jurjees
Citations
Altmetric:
Abstract
Background: Olaparib (O) was first poly ADP-ribose polymerase inhibitor (PARPi)
approved for use in the UK as maintenance therapy in relapsed BRCA mutated ovarian
cancer in 2017. Since then Niraparib (N) and Rucaparib (R) have also been approved
as maintenance therapy in patients with relapsed ovarian cancer with and without
BRCA gene mutations. Though clinicians now have three drugs to choose from, a lack
of head-to-head data means the choice is not a straight forward one. We aim to
compare toxicities of the PARPi drugs in order to give clinicians a better idea of which
drugs to use in certain scenarios. We report the real world experience of the three
PARPi at a UK cancer centre.
Methods: Retrospective data was collected from every patient with a gynaecological
cancer who had a PARPi up to the 19th of March 2020. Data lock was the 10th of May
2020.
Results: 119 patients with relapsed platinum-sensitive ovarian/fallopian tube or primary
peritoneal cancer were included. The group contained 72 patients with BRCA
wild-type (wtBRCA), 46 patients with germline mutated BRCA (gBRCA) and one patient
with an unknown BRCA status. 71 patients received N, 37 received O and12
patients received R. gBRCA patients were more likely to receive O. wtBRCA patients
were more likely to receive N or R. The median number of cycles was 5. The preliminary
median PFS for the gBRACA population is 14.9 months. The preliminary
median PFS for the wtBRACA population is 7.2 months. Treatment interruption, dose
reduction and early stoppage all favoured O. The incidence of grade 3 cytopenia was
similar across the three drugs. Derangement of liver function, abdominal pain,
nausea, vomiting and diarrhoea was observed more often with R. Hypertension,
insomnia, mucositis and dyspnoea were seen with more often with N. Evaluation of
correlation between BRCA status and incidence of adverse events is ongoing. 41
patients have thus far completed chemotherapy post progression on PARPi. The
myelosupressive effects of chemotherapy post-PARPi and its correlations with the
individual drugs and BRCA status is being evaluated. Mature data will be presented at
the meeting.
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 76.09 KB
Keywords
Type
Meetings and Proceedings
Citation
Nagy B, Morgan RD, Jayson GC, Mitchell C, Clamp AR, Hasan JH. 822P Comparison of toxicities of PARP inhibitors used in gynaecological cancers observed at a large cancer centre. Annals of Oncology. 2020;31:S621-S.